Rezolute (RZLT) to Release Earnings on Wednesday

Rezolute (NASDAQ:RZLT - Get Free Report) will likely be posting its Q3 2025 quarterly earnings results before the market opens on Wednesday, May 21st. Analysts expect Rezolute to post earnings of ($0.22) per share for the quarter.

Rezolute (NASDAQ:RZLT - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). On average, analysts expect Rezolute to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Rezolute Stock Performance

RZLT opened at $3.67 on Wednesday. The company's 50 day simple moving average is $3.24 and its 200 day simple moving average is $4.34. Rezolute has a 1 year low of $2.22 and a 1 year high of $6.19. The stock has a market capitalization of $222.16 million, a PE ratio of -3.01 and a beta of 1.01.

Insider Buying and Selling at Rezolute

In other news, Director Wladimir Hogenhuis bought 10,000 shares of Rezolute stock in a transaction dated Tuesday, February 18th. The shares were acquired at an average cost of $4.70 per share, with a total value of $47,000.00. Following the completion of the transaction, the director now owns 77,267 shares in the company, valued at approximately $363,154.90. This trade represents a 14.87% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Nevan C. Elam bought 12,302 shares of Rezolute stock in a transaction dated Thursday, March 27th. The shares were purchased at an average cost of $2.85 per share, for a total transaction of $35,060.70. Following the completion of the transaction, the chief executive officer now owns 224,119 shares of the company's stock, valued at approximately $638,739.15. This represents a 5.81% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 39,060 shares of company stock valued at $130,694 over the last ninety days. Corporate insiders own 18.39% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on RZLT shares. JMP Securities raised their target price on shares of Rezolute from $8.00 to $9.00 and gave the stock a "market outperform" rating in a research report on Thursday, February 13th. Craig Hallum raised shares of Rezolute to a "strong-buy" rating in a research report on Tuesday, February 4th. HC Wainwright reissued a "buy" rating and issued a $14.00 target price on shares of Rezolute in a research report on Monday, April 28th. Finally, Guggenheim reissued a "buy" rating on shares of Rezolute in a research report on Monday, February 10th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $26.43.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.